Exicure, Inc. (XCUR)
Nasdaq · Healthcare · Biotechnology
$1.07−6.96%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.0M
- 52-week range
- $1.05 – $9.48
- 52-week change
- −73.32%
- EPS (trailing)
- −$1.31
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$4.9M
- Diluted EPS
- −$0.79
- Free cash flow
- −$8.6M
From the company’s annual report on SEC EDGAR.
About Exicure, Inc.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Headquarters: Redwood City, United States · 1 employees · exicuretx.com